A DaSH-Global White Paper

Will Disruptive Innovation Cure Health Care?

27 April 2020


Lee Wemyss

Idea in Brief - from Havard Business Review (HBR)

Book HBR must read.png

All health care industries in the developed world are ailing. The symptoms? Expensive, inconvenient delivery systems that leave more and more consumers dissatisfied. Why? Major health care institutions have "overshot" the level of care most patients need. Researchers and practitioners focus on the most complicated diseases, while paying
insufficient attention to the needs of patients with more common care needs.

The cure? All health care industry players must embrace dlsruptlve innovations: cheaper, simpler more convenient products or services that ultimately let less expensive professionals provide sophisticated service in affordable settings. Consider angioplasty used by cardiologists with

patients who not long ago would have needed invasive costly surgery by open-heart specialists. Or the latest blood glucose meters, which allow diabetic patients to monitor their own health-accurately, conveniently and inexpensively.

We need many more of these disruptive innovations to revitalize the health care industry. Companies that develop them will grow profitably with less invest-
ment. Hospitals and managed-care institutions will stem their financial hemorrhaging. When industry players and consumers join forces to promote affordable, high-quality medical services, everyone will win.

by Clayton M Christensen, Richard Bohmer, and John Kenagy

The Theory of Disruptive Innovation has gone from a management theory first published in 1997 by CM Christensen to the new normal in  American Healthcare.



Graph Source:
CM Christensen, The Innovator's Dilemma: When New Technologies Cause Great Firms to Fail (Boston: Harvard Business School Press, 1997)

disrupter graph.jpg


Our disruptive technology, the DAX Companion, starts simply by addressing both a patient and a service niche unmet need.  

The DAX Companions support patients and their famillies AT HOME putting them in control of their own health data through a digital companion they can use on their phone, tablet or over the internet. Patients and their families can record: symptoms, outcomes or via wearables, information that is important to them, to see how well they're doing. They can also record how well their services are doing, and better communicate their healthcare needs.

For the service, the companion will very efficiently harness the public's ability to be co-producer of their own care, as well as provide the service with invaluable intelligence for delivery as well as research. (As the covid-19 panademic has shown so clearly: good real-time data is an absolute essential aid for focusing and optimising resources.)


The investment needed to support the DAX Companions comes from multi-sponsor commercial research. DaSH Global work alongside Patient Advocacy and Clinical Societies to ensure this works for the benefit of patients: 

  • working out what patient's need;

  • collecting patients outcomes: how their disease is impacting them and their families day-to-day life;

  • protecting patient annonimity;

  • ensuring data control and oversight;

  • and, putting monies back into the patient's advocacy group.


Health services DO NOT ROUTINELY COLLECT patient reported outcomes - but it is an absolutely essential resource for understanding how effective treatments are at improving quality of life.


Drug trials alone are no longer seen as sufficient by goverments or regulators. 'Use once' or as we call them 'oxbow lake'  data studies are increasingly seen as an unsustainable option by industry.  Integrated ongoing real-world evidence offers significant benefits to all and ultimately more effective lower cost healthcare. 

Over time the DAX Companion will adapt to support new ways of working, co-ordinating and enabling interventions to be undertaken in more convenient and less expensive settings that will ultimately disrupt conventional primary as well as tertiary service delivery.  

We also expect, over time, that these initialy small (but national) disease specific data collection tools will quickly change and adapt to disrupt the current real-world data research market!

A DaSH-Global White Paper


© 2023 by Dash-Global Ltd. (using WIX)

Back to top